- Page 1 and 2: The Toxicologist Supplement to Toxi
- Page 3 and 4: The Toxicologist Supplement to Toxi
- Page 5 and 6: 1 BIOLOGICAL PATHWAY ANALYSIS: AN I
- Page 7 and 8: 11 ICH INITIATIVES FOR CONDUCTING P
- Page 9 and 10: models. Experimental approaches and
- Page 11 and 12: 30 SILICA AND ASBESTOS IMMUNOTOXICI
- Page 13 and 14: 40 NONCANCER TOXICITY POTENTIAL AT
- Page 15 and 16: ased products for patient administr
- Page 17 and 18: nase regulates Hsp27-induced reorga
- Page 19 and 20: exposure resulted in splenomegaly.
- Page 21: We investigated the effect of imati
- Page 25 and 26: 98 DERIVING SIGNATURES OF IN VIVO T
- Page 27 and 28: sulfate, cinnamic aldehyde, 2,4-din
- Page 29 and 30: The final product will be a system
- Page 31 and 32: mercially available STP brands by m
- Page 33 and 34: for six weeks, with 10 mg/kg azoxym
- Page 35 and 36: eceived RES post-TCDD exposure when
- Page 37 and 38: morigenesis. Knocking down of JARID
- Page 39 and 40: 163 MICROPET IMAGING OF [18F]-DFNSH
- Page 41 and 42: These results are comparable to tha
- Page 43 and 44: activity as assessed by lever press
- Page 45 and 46: for measured physico-chemical param
- Page 47 and 48: 199 DEVELOPMENT OF A MULTIPARAMETER
- Page 49 and 50: To cause PLD, a drug needs to enter
- Page 51 and 52: In contrast to the parent PBDEs and
- Page 53 and 54: transiently transfected HEK 293 cel
- Page 55 and 56: TCDD exposure, 24 h prior to a 20 %
- Page 57 and 58: 244 NON-ADDITIVE EFFECTS OF PCB153
- Page 59 and 60: 253 COMPARISON OF MIXTURE TOXICITY
- Page 61 and 62: two cerium oxide nanoparticles of v
- Page 63 and 64: 271 SIZE-DEPENDENT EFFECTS OF TUNGS
- Page 65 and 66: adigms such as Tox 21 and Toxcast,
- Page 67 and 68: QDs with emission maximum at 800nm
- Page 69 and 70: Cleveland, while others were found
- Page 71 and 72: without the need of animal testing.
- Page 73 and 74:
Conclusions: These results are cons
- Page 75 and 76:
ing oxime reactivation and organoph
- Page 77 and 78:
335 A NON-OXIME IMPROVES SURVIVAL I
- Page 79 and 80:
alties suffer from permanent lung i
- Page 81 and 82:
ies have established inflammatory b
- Page 83 and 84:
363 GENETIC VARIATION IN ISOGENIC M
- Page 85 and 86:
372 EVALUATING THE BIOLOGICAL INTER
- Page 87 and 88:
dose of 1/20 LD50 (400 mg/kg.bwt) f
- Page 89 and 90:
median CR-adjusted isoflavone conce
- Page 91 and 92:
data indicate that AhR deletion pro
- Page 93 and 94:
February 2006). The rabbit is one o
- Page 95 and 96:
tal neurotoxicity (DNT) test (OECD
- Page 97 and 98:
of selected microorganisms that are
- Page 99 and 100:
BVI. Histopathological analysis was
- Page 101 and 102:
446 MOLECULAR CLONING AND CHARACTER
- Page 103 and 104:
portant in predicting risk. CYPs 1A
- Page 105 and 106:
ats, which involves metabolic activ
- Page 107 and 108:
473 BOVINE CORNEAL OPACITY AND PERM
- Page 109 and 110:
482 TYPE III DEIODINASE (D3) IS PRO
- Page 111 and 112:
tancy evaluation and ranking of bat
- Page 113 and 114:
501 CHARACTERIZATION OF ESTERASE, G
- Page 115 and 116:
510 REDOX CYCLING BY ENDOGENOUS 2-
- Page 117 and 118:
prostate cancer cells. All 8 BEL de
- Page 119 and 120:
metallic nickel nanoparticles. Acti
- Page 121 and 122:
variety of more or less reactive ch
- Page 123 and 124:
550 QUALIFICATION STRATEGIES-GENOTO
- Page 125 and 126:
ferentiation, and 3) how mixtures o
- Page 127 and 128:
572 LOW-CHRONIC ARSENIC EXPOSURE: E
- Page 129 and 130:
582 IDENTIFICATION OF SENSITIVE URI
- Page 131 and 132:
duced by the genetic outcross of fe
- Page 133 and 134:
fects of new compounds are equally
- Page 135 and 136:
acterize the current state of the s
- Page 137 and 138:
620 CHARACTERIZATION OF POTENTIAL I
- Page 139 and 140:
ways. Moreover, both MAP kinase and
- Page 141 and 142:
641 POPS IN THE U.S. POPULATION AND
- Page 143 and 144:
studies such as the NCS, consider h
- Page 145 and 146:
the beginning of the academic caree
- Page 147 and 148:
trophil infiltration, a significant
- Page 149 and 150:
tactic response and optokinetic res
- Page 151 and 152:
usually high spontaneous PIG-A MFs.
- Page 153 and 154:
699 PROMUTAGEN ACTIVATION AND P450
- Page 155 and 156:
oxodG in bone marrow, spleen, kidne
- Page 157 and 158:
718 GENOTOXICITY OF ORGANIC EXTRACT
- Page 159 and 160:
ment were 18.0 and 4.5 nM for BEAS-
- Page 161 and 162:
strongest activation of nuclear fac
- Page 163 and 164:
746 MACROPHAGE INHIBITORY CYTOKINE-
- Page 165 and 166:
screening of cell migration. High-c
- Page 167 and 168:
dase inhibition). In contrast, inhi
- Page 169 and 170:
mice; the decrease was more pronoun
- Page 171 and 172:
Markers of oxidative damage reached
- Page 173 and 174:
793 PULMONARY RESPONSE, OXIDATIVE S
- Page 175 and 176:
cilitate clinical and industrial ap
- Page 177 and 178:
sion of p-p38, p-p53, p21 and cycli
- Page 179 and 180:
821 KIDNEY INJURY MOLECULE-2 GENE D
- Page 181 and 182:
commercial applications, and have b
- Page 183 and 184:
developmental effects. The residual
- Page 185 and 186:
strand breaks in an in vitro model
- Page 187 and 188:
etate (immunotoxicity). 2,4-D was t
- Page 189 and 190:
867 MELATONIN AMELIORATES CYCLOPHOS
- Page 191 and 192:
pharmacokinetic (PBPK) models. Ten
- Page 193 and 194:
of radiolabeled Mn (carrier-free 54
- Page 195 and 196:
893 UNVEILING ASSOCIATIONS BETWEEN
- Page 197 and 198:
using area under the concentration
- Page 199 and 200:
912 COMMERCIAL FISH DIETS INDUCE VI
- Page 201 and 202:
922 A STUDY OF PHOTOTOXICITY FOLLOW
- Page 203 and 204:
from 0.1 to 2.9 g/L (saturated vapo
- Page 205 and 206:
vasive method for assessing several
- Page 207 and 208:
950 ARSENITE DOWN-REGULATES THE CAR
- Page 209 and 210:
inflammatory signaling is altered b
- Page 211 and 212:
treated wood. Seventy-five of 132 w
- Page 213 and 214:
ergy homeostasis and raising levels
- Page 215 and 216:
treated with mercury and then with
- Page 217 and 218:
997 IN VIVO CORRELATES OF THE MANGA
- Page 219 and 220:
of the panel. The panel was compris
- Page 221 and 222:
sponse, location, and severity scor
- Page 223 and 224:
tant source of n-3 fatty acids such
- Page 225 and 226:
old for serious, irreversible or es
- Page 227 and 228:
1045 SUBCHRONIC TOXICITY EVALUATION
- Page 229 and 230:
sites collected 3 days after inject
- Page 231 and 232:
1063 MOLECULAR MECHANISM OF OLANZAP
- Page 233 and 234:
esponses, and can be available for
- Page 235 and 236:
hence more physiologically relevant
- Page 237 and 238:
thesized apoproteins, so we tested
- Page 239 and 240:
vate CYP3A5 but could be released b
- Page 241 and 242:
1108 STYRENE-INDUCED TOXIC EFFECTS
- Page 243 and 244:
1118 THE PRESENCE OF DIETHYL FUMARA
- Page 245 and 246:
zebrafish cells were first exposed
- Page 247 and 248:
utene-1,4-dial, which has been show
- Page 249 and 250:
groups, largely due to lower non-HD
- Page 251 and 252:
Exposure to gluten in individuals w
- Page 253 and 254:
contrast to VGSC activators such as
- Page 255 and 256:
1175 70% HYDROFLUORIC ACID (HF) CUT
- Page 257 and 258:
axis. An increase in hyaline drople
- Page 259 and 260:
1194 esiRNA AND siRNA HIGH-THROUGHP
- Page 261 and 262:
1203 ARYL HYDROCARBON RECEPTOR-DNA
- Page 263 and 264:
permeability (calcein), mitochondri
- Page 265 and 266:
olytic caspase activation, caspase-
- Page 267 and 268:
teristics of a human T-type voltage
- Page 269 and 270:
80% of the activity from the yellow
- Page 271 and 272:
1251 DEVELOPMENTAL EXPOSURE TO DELT
- Page 273 and 274:
1260 MANEB ENHANCES MPP + -INDUCED
- Page 275 and 276:
demonstrated by knockdown of beclin
- Page 277 and 278:
1278 PINK1 AND MITOCHONDRIAL DYNAMI
- Page 279 and 280:
treatment for number of live worms.
- Page 281 and 282:
1297 INVESTIGATION OF THE NEUROTOXI
- Page 283 and 284:
1306 DEVELOPMENT OF AN IN VITRO ASS
- Page 285 and 286:
1315 EVALUATION OF 3- AND 1-METHYLH
- Page 287 and 288:
prior to kainic acid-induced seizur
- Page 289 and 290:
1334 AFFECT OF GENETIC VARIATION ON
- Page 291 and 292:
1346 THE OTHER WORLD OF THE TRANSCR
- Page 293 and 294:
strate, leading to excess microvesi
- Page 295 and 296:
1368 OVERVIEW OF THERAPEUTIC VACCIN
- Page 297 and 298:
to a bovine adrenal cortical epithe
- Page 299 and 300:
DOTC had no effects. These results
- Page 301 and 302:
1398 PULMONARY TOXICITY OF CERIUM D
- Page 303 and 304:
PPARα, LXR, ER, AR and AhR activit
- Page 305 and 306:
1417 MECHANISM OF GENDER-DIVERGENT
- Page 307 and 308:
els, they disrupt homeostatic contr
- Page 309 and 310:
were to characterize exposure of th
- Page 311 and 312:
1448 ADVERSE OUTCOME PATHWAYS AND E
- Page 313 and 314:
the level in urine was 25% of the m
- Page 315 and 316:
1;akt-2 double mutant and pdk-1 mut
- Page 317 and 318:
jury effects when compared to contr
- Page 319 and 320:
tude than equivalent oral doses. Af
- Page 321 and 322:
cells; and increased iNOS and MCP-1
- Page 323 and 324:
B6.Cg-Kit W-sh mice. These findings
- Page 325 and 326:
1511 STATIN-TREATMENT EFFECTIVELY R
- Page 327 and 328:
1520 EFFECT OF INHALATION EXPOSURE
- Page 329 and 330:
numbers of IFN-γ producing cells w
- Page 331 and 332:
These data indicate that TCDD treat
- Page 333 and 334:
esponse to allogenic cells, where P
- Page 335 and 336:
larly suppressed LPS-induced TNF-α
- Page 337 and 338:
1565 INFLUENCE OF EXPOSURE ROUTE AN
- Page 339 and 340:
veloping animals to adverse effects
- Page 341 and 342:
the observed CL values were 0.07 L/
- Page 343 and 344:
which is most relevant for potentia
- Page 345 and 346:
tive impairment, suggesting that ox
- Page 347 and 348:
1611 AN IN VITRO METABOLOMICS APPRO
- Page 349 and 350:
Expression of the β6 integrin (Itg
- Page 351 and 352:
ats (10 μg/kg TCDD). Here we repor
- Page 353 and 354:
at liver slices and how the metabon
- Page 355 and 356:
with gender differences in AUC and
- Page 357 and 358:
oxetine (30 mg/kg reduced to 15 mg/
- Page 359 and 360:
eleased from necrotic cells where i
- Page 361 and 362:
plants, they are present in surface
- Page 363 and 364:
ferentiation (quantitative in-cell
- Page 365 and 366:
control for macrophage activation).
- Page 367 and 368:
to 0.5μg/ml. Minimal inhibitory co
- Page 369 and 370:
lines tested. Given that dex and AT
- Page 371 and 372:
tion in the absence of an immune re
- Page 373 and 374:
treated rats had lower calcium load
- Page 375 and 376:
1740 PROFILING COMPOUNDS WITH CARDI
- Page 377 and 378:
dothelial cells confirmed caveolin-
- Page 379 and 380:
1758 GINKGO BILOBA EXTRACT INDUCES
- Page 381 and 382:
arin-induced suppression of MDR1 ex
- Page 383 and 384:
1780 ANTIANDROGENIC AND ANTIPROLIFE
- Page 385 and 386:
included in the evaluation, most of
- Page 387 and 388:
1799 GUIDANCE ON THE APPLICATION OF
- Page 389 and 390:
However, substances with EC3 values
- Page 391 and 392:
1816 CD-INDUCED EGFR TRANSACTIVATIO
- Page 393 and 394:
1826 KERATIN 7 EXPRESSION IN INDEPE
- Page 395 and 396:
centa were collected at the time of
- Page 397 and 398:
1845 SYSTEMATIC SCREENING OF YEAST
- Page 399 and 400:
underlying the development of co-mo
- Page 401 and 402:
eing measured in experimental roden
- Page 403 and 404:
ufactured in the US for more than 3
- Page 405 and 406:
nine (N7-THB-Gua) and N7-hydroxyphe
- Page 407 and 408:
1892 EFFECT OF LAMBDA-CYHALOTHRIN O
- Page 409 and 410:
22 in Phase I. Antimicrobial pestic
- Page 411 and 412:
kinetic and dynamic differences, an
- Page 413 and 414:
iphenyl, saccharin and melamine was
- Page 415 and 416:
1930 DEVELOPMENT OF A RELATIVE SOUR
- Page 417 and 418:
1939 MODE OF ACTION FOR THE CANCER
- Page 419 and 420:
human was about 1.5-fold lower (60
- Page 421 and 422:
Disruption of BDEC integrity in alp
- Page 423 and 424:
1968 A HUMAN HEPG2 LUCIFERASE ASSAY
- Page 425 and 426:
in the offspring during tumor devel
- Page 427 and 428:
een developed to investigate perfus
- Page 429 and 430:
to 131.73 μg/mL for KLH-specific I
- Page 431 and 432:
cell lines (ATCC) were cultured in
- Page 433 and 434:
flammation and xenobiotic metabolis
- Page 435 and 436:
vide many contributions: with its g
- Page 437 and 438:
to-metal joint replacement. For exa
- Page 439 and 440:
to be addressed or negotiated. Deci
- Page 441 and 442:
especially with anti-TNF therapies.
- Page 443 and 444:
genic line Tg(are:eGFP) was created
- Page 445 and 446:
2074 COMPUTATIONAL ASSESSMENT OF TH
- Page 447 and 448:
2084 INHIBITION OF 11β-HSD1 DECREA
- Page 449 and 450:
(T) and express several enzymes inv
- Page 451 and 452:
2101 GENISTEIN MODULATION OF BLOOD
- Page 453 and 454:
males per group were dosed orally o
- Page 455 and 456:
ate the feasibility of assessing re
- Page 457 and 458:
changed. Hepatic protein carbonyl l
- Page 459 and 460:
sought to examine alterations in he
- Page 461 and 462:
2147 A SINGLE AMINO ACID CONTROLS T
- Page 463 and 464:
Gstm7) was independent of both CAR
- Page 465 and 466:
ility of tungsten trioxide (WO3), t
- Page 467 and 468:
ured by real-time PCR array and rel
- Page 469 and 470:
glucose, and creatinine levels, and
- Page 471 and 472:
Several studies have reported suppr
- Page 473 and 474:
exposure between TCDD-exposed labor
- Page 475 and 476:
Furthermore, with increasing number
- Page 477 and 478:
Society of Toxicology 2010 Author I
- Page 479 and 480:
Society of Toxicology 2010 Author I
- Page 481 and 482:
Society of Toxicology 2010 Author I
- Page 483 and 484:
Society of Toxicology 2010 Author I
- Page 485 and 486:
Society of Toxicology 2010 Author I
- Page 487 and 488:
Society of Toxicology 2010 Author I
- Page 489 and 490:
Society of Toxicology 2010 Author I
- Page 491 and 492:
Society of Toxicology 2010 Author I
- Page 493 and 494:
Society of Toxicology 2010 Author I
- Page 495 and 496:
Society of Toxicology 2010 Author I
- Page 497 and 498:
Society of Toxicology 2010 Author I
- Page 499 and 500:
Society of Toxicology 2010 Author I
- Page 501 and 502:
Society of Toxicology 2010 Abstract
- Page 503 and 504:
Society of Toxicology 2010 Abstract
- Page 505 and 506:
Society of Toxicology 2010 Abstract
- Page 507 and 508:
Society of Toxicology 2010 Abstract
- Page 509 and 510:
Society of Toxicology 2010 Abstract
- Page 511 and 512:
Society of Toxicology 2010 Abstract
- Page 513 and 514:
49 th Annual Meeting and ToxExpo A
- Page 515 and 516:
49 th Annual Meeting and ToxExpo A
- Page 517 and 518:
49 th Annual Meeting and ToxExpo A
- Page 519 and 520:
49 th Annual Meeting and ToxExpo A
- Page 521 and 522:
49 th Annual Meeting and ToxExpo A
- Page 523 and 524:
49 th Annual Meeting and ToxExpo A
- Page 525 and 526:
49 th Annual Meeting and ToxExpo A
- Page 527 and 528:
49 th Annual Meeting and ToxExpo A
- Page 529 and 530:
49 th Annual Meeting and ToxExpo A
- Page 531 and 532:
49 th Annual Meeting and ToxExpo A
- Page 533 and 534:
49 th Annual Meeting and ToxExpo A
- Page 535 and 536:
49 th Annual Meeting and ToxExpo A
- Page 537 and 538:
49 th Annual Meeting and ToxExpo A
- Page 539 and 540:
49 th Annual Meeting and ToxExpo A
- Page 541 and 542:
49 th Annual Meeting and ToxExpo A
- Page 543 and 544:
49 th Annual Meeting and ToxExpo A
- Page 545 and 546:
49 th Annual Meeting and ToxExpo A
- Page 547 and 548:
The Official Journal of the Society